Can a marketplace rebuild trust and enable global genomic data sharing across geopolitical divides? The next generation of biotechnology depends on unlocking the 99.9% of non-human genomic data that remains unsequenced or unshared. Yet this data is geographically uneven, often sovereign, and shaped by histories of extraction that undermine trust and create legal and policy barriers. This session explores how Fairfield Bio addresses these realities through marketplace dynamics that incentivize broad contribution.

Speakers

• Kevin Slavin, MD and Co-Founder, Fairfield Bio

• Mitch Wolfe, CEO and Co-Founder, Fairfield Bio